CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 39 enrolled
Drug / intervention
Peginterferon alfa-2adrug
Likely dose
Peginterferon alfa-2a 180 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00436163
NCT00436163Phase 4Completed
CompareCT.gov

Baltic Post-marketing Program of PEGASYS (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B

Hoffmann-La Roche·interventional·Posted Feb 16, 2007·Updated Oct 24, 2016

In Brief

A Phase 4 clinical trial evaluating Peginterferon alfa-2a for Hepatitis B, Chronic. Completed, enrolled 39 participants across 9 sites in 3 countries.

Detailed Summary

This single-arm study will evaluate the efficacy and safety of peginterferon alfa-2a in treatment-naive Baltic participants with Hepatitis B envelope antigen (HBeAg)-positive chronic Hepatitis B virus (HBV). All participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneously once weekly. Following 48 weeks of treatment, there will be a 24 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is less than 100 participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesEstonia, Latvia, Lithuania
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 16, 2007
Enrollment StartMar 1, 2007
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 19.4 years ago

Interventions

Peginterferon alfa-2adrug

180 mcg subcutaneously once per week for 48 weeks.